Teva deal ties up Shire's Intuniv loose end
This article was originally published in Scrip
Executive Summary
Shire has settled litigation with Teva Pharmaceuticals USA over Shire's extended-release Intuniv (guanfacine) tablets to treat attention-deficit hyperactivity disorder. The deal ties up a loose end left over after Shire recently agreed a settlement with another generic challenger, Actavis.